TuHURA Biosciences (NASDAQ:HURA - Free Report) - Investment analysts at Zacks Small Cap lifted their Q3 2025 earnings per share estimates for shares of TuHURA Biosciences in a research report issued on Monday, April 14th. Zacks Small Cap analyst J. Vandermosten now expects that the company will earn ($0.14) per share for the quarter, up from their previous estimate of ($0.15). Zacks Small Cap also issued estimates for TuHURA Biosciences' Q4 2025 earnings at ($0.14) EPS, Q1 2026 earnings at ($0.15) EPS and Q2 2026 earnings at ($0.15) EPS.
Separately, HC Wainwright dropped their price target on TuHURA Biosciences from $13.00 to $12.00 and set a "buy" rating on the stock in a research note on Thursday, April 3rd.
Get Our Latest Analysis on TuHURA Biosciences
TuHURA Biosciences Stock Performance
NASDAQ:HURA remained flat at $4.15 during mid-day trading on Wednesday. 109,538 shares of the company traded hands, compared to its average volume of 267,747. The stock has a fifty day simple moving average of $3.27. TuHURA Biosciences has a 52-week low of $1.80 and a 52-week high of $7.93.
Institutional Investors Weigh In On TuHURA Biosciences
Several institutional investors and hedge funds have recently bought and sold shares of HURA. Geode Capital Management LLC bought a new stake in shares of TuHURA Biosciences in the 4th quarter worth approximately $1,084,000. Suncoast Equity Management bought a new position in shares of TuHURA Biosciences during the 4th quarter valued at $421,000. Apollon Wealth Management LLC bought a new stake in TuHURA Biosciences during the fourth quarter worth approximately $253,000. Northern Trust Corp acquired a new position in TuHURA Biosciences during the 4th quarter worth $234,000. Finally, Squarepoint Ops LLC bought a new position in TuHURA Biosciences in the 4th quarter worth approximately $223,000. Institutional investors and hedge funds own 0.62% of the company's stock.
About TuHURA Biosciences
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Further Reading
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
